Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Risk of Herpes zoster in patients with psoriasis treated with biologic drugs

Risk of Herpes zoster in patients with psoriasis treated with biologic drugs Background Little is known about the risk of herpes zoster (HZ), among patients with psoriasis treated with biologic drugs. Objective To determine the incidence of HZ in patients with psoriasis and the association between HZ and use of biologic drugs in these patients. Methods The study was performed utilizing the medical database of Clalit Health Services in Israel. The incidence of HZ events was calculated among patients with psoriasis treated with phototherapy, traditional systemic medications and biologic drugs. Incidence rates of HZ events were calculated for each medication, as well as hazard ratios adjusted for age, sex and healthcare utilization burden. Results Among 22 330 psoriasis patients (215 656 person‐years), 1321 HZ cases were diagnosed. The crude incidence rates per 1000 person‐years were 6.0 for UVB phototherapy (95% confidence interval (CI), 0–12.8), 10.1 for PUVΑ (1.3–19.0), 5.4 for acitretin (2.2–8.7), 17.0 for methotrexate (10.6–23.4), 13.9 for etanercept (0.3–27.4), 19.3 for infliximab (0–45.8) and 4.6 for controls (CI, 4.3–5.0). No cases of HZ were seen among patients treated with alefacept, efalizumab or adalimumab. In a multivariate analysis, age, female sex, healthcare utilization pattern and corticosteroid treatment were associated with the time to HZ infection. The association of HZ with infliximab approached statistical significance (Hazard ratio: 1.77, 95% CI: 0.92–3.43), but none of the other biologic drugs were significantly associated with the risk of HZ. Conclusion Among patients with psoriasis, treatment with some biologic drugs was associated with a higher incidence of HZ compared with controls, though the difference was not statistically significant. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Risk of Herpes zoster in patients with psoriasis treated with biologic drugs

Loading next page...
 
/lp/wiley/risk-of-herpes-zoster-in-patients-with-psoriasis-treated-with-biologic-PzkQVJXvB5

References (30)

Publisher
Wiley
Copyright
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
DOI
10.1111/j.1468-3083.2011.04230.x
pmid
21923837
Publisher site
See Article on Publisher Site

Abstract

Background Little is known about the risk of herpes zoster (HZ), among patients with psoriasis treated with biologic drugs. Objective To determine the incidence of HZ in patients with psoriasis and the association between HZ and use of biologic drugs in these patients. Methods The study was performed utilizing the medical database of Clalit Health Services in Israel. The incidence of HZ events was calculated among patients with psoriasis treated with phototherapy, traditional systemic medications and biologic drugs. Incidence rates of HZ events were calculated for each medication, as well as hazard ratios adjusted for age, sex and healthcare utilization burden. Results Among 22 330 psoriasis patients (215 656 person‐years), 1321 HZ cases were diagnosed. The crude incidence rates per 1000 person‐years were 6.0 for UVB phototherapy (95% confidence interval (CI), 0–12.8), 10.1 for PUVΑ (1.3–19.0), 5.4 for acitretin (2.2–8.7), 17.0 for methotrexate (10.6–23.4), 13.9 for etanercept (0.3–27.4), 19.3 for infliximab (0–45.8) and 4.6 for controls (CI, 4.3–5.0). No cases of HZ were seen among patients treated with alefacept, efalizumab or adalimumab. In a multivariate analysis, age, female sex, healthcare utilization pattern and corticosteroid treatment were associated with the time to HZ infection. The association of HZ with infliximab approached statistical significance (Hazard ratio: 1.77, 95% CI: 0.92–3.43), but none of the other biologic drugs were significantly associated with the risk of HZ. Conclusion Among patients with psoriasis, treatment with some biologic drugs was associated with a higher incidence of HZ compared with controls, though the difference was not statistically significant.

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Sep 1, 2012

There are no references for this article.